Lexicon Pharmaceuticals | LXRX - Umlaufvermögen





Umlaufvermögen Veränderung Datum
Abbott USD 25.51B 488M 2026-03
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Akebia Therapeutics USD 252.96M 5.38M 2025-12
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
AstraZeneca USD 29.61B 890M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Coherus Biosciences USD 206.71M 254.25M 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Illumina USD 2.74B 551M 2026-03
Insmed USD 1.79B 137.6M 2025-12
Ironwood Pharmaceuticals USD 273.84M 82.09M 2025-09
J&J USD 59.17B 3.55B 2026-03
Lexicon Pharmaceuticals USD 101.9M 20.63M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
MannKind USD 291.58M 67.26M 2025-12
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.77B 774M 2026-03
Novartis USD 26.61B 3.85B 2026-03
PTC Therapeutics USD 2.27B 266.14M 2025-12
Puma Biotechnology USD 143.58M 7M 2025-09
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Thermo Fisher Scientific USD 22.32B 6.39B 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12